unveiled plans to construct an R&D center in Beijing. Expected to open in 2010, the site will cost about $90 million. The 200,000 sq. ft. facility will be able to accommodate 350 employees, Genzyme reports.
The firm will conduct research in orthopedics, oncology, and endocrinology as well as transplant, immune, and cardiovascular diseases at this center. It will also include laboratory-scale operations for MACI® (matrix-induced autologous chondrocyte implantation) cell therapy and polyclonal antibody operations.
The facility will feature an environmentally clean design. It will incorporate features like a living roof to reduce pollution caused by storm-water runoff, a solar thermal system that will provide a significant portion of the building's hot water and reduce its energy consumption, and low-flow fixtures to limit water usage. An all-glass exterior will provide employees with significant natural light, reducing the building’s dependence on electricity.